Search
Now showing items 1-9 of 9
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
(2018-04)
Background: A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment. Objective: ...
e-Health and multiple sclerosis: An update.
(2018-11)
e-Health (or digital healthcare) is becoming increasingly relevant in multiple sclerosis (MS) clinical management. We aim to review and discuss current status and future perspective of e-health in people with multiple ...
Alemtuzumab depletion failure can occur in multiple sclerosis.
(2018-06)
Alemtuzumab is a lymphocyte-depleting antibody and one of the most effective treatments for relapsing multiple sclerosis. However, it also causes loss of immune-tolerance leading to secondary autoimmunity and marked anti-drug ...
Magnetic resonance imaging correlates of neuro-axonal pathology in the MS spinal cord.
(2018-09)
In people with multiple sclerosis (MS), the spinal cord is the structure most commonly affected by clinically detectable pathology at presentation, and a key part of the central nervous system involved in chronic disease ...
Neuromyelitis optica spectrum disorder presenting as rhomboencephalitis.
(2018-05-23)
Rhomboencephalitis, at least in its acute phase, is often a severely disabling syndrome, and can be life threatening. A range of underlying conditions can lead to this clinical syndrome. Rapid diagnosis to initiate treatment ...